(VRTX) Vertex Pharmaceuticals - Ratings and Ratios
Cystic Fibrosis, Gene Therapy, Sickle Cell, Thalassemia, Pain Relief
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 24.3% |
| Value at Risk 5%th | 38.5% |
| Relative Tail Risk | -3.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.43 |
| Alpha | 1.72 |
| CAGR/Max DD | 0.57 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.308 |
| Beta | 0.425 |
| Beta Downside | 0.169 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.07% |
| Mean DD | 7.86% |
| Median DD | 6.29% |
Description: VRTX Vertex Pharmaceuticals December 02, 2025
Vertex Pharmaceuticals (NASDAQ:VRTX) is a U.S. biotech focused on cystic fibrosis (CF), commercializing a suite of CFTR modulators-including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO-that together address >90 % of the CF genotype spectrum and generate the bulk of the company’s revenue (≈ $7 billion FY 2023). The firm also pursues non-CF indications such as sickle-cell disease (CASGEVY), acute pain (JOURNAVX), and gene-editing platforms through collaborations with CRISPR Therapeutics, Moderna, and Entrada Therapeutics.
Key pipeline milestones include VX-522 (CFTR-mRNA therapy, Phase 1/2), inaxaplin (APOL1-mediated kidney disease, Phase 2), and early-stage programs for type 1 diabetes (VX-880, VX-264) and myotonic dystrophy (VX-670). As of Q4 2024, Vertex’s R&D spend was ≈ $2.1 billion, reflecting a ≈ 30 % increase YoY, while its cash runway exceeds $10 billion, providing flexibility to advance these high-risk assets.
Sector-wide drivers-rising prevalence of rare-disease diagnoses, expanding payer willingness to fund high-value gene-editing therapies, and a ~ 12 % CAGR in the global CF market-support Vertex’s growth outlook, but pricing scrutiny and competitive gene-therapy entrants remain material risks. For a deeper, data-rich view of how Vertex’s valuation stacks up against these dynamics, a quick look at ValueRay’s analyst toolkit can be useful.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (3.68b TTM) > 0 and > 6% of Revenue (6% = 703.4m TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 19.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 51.98% (prev 54.89%; Δ -2.91pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 3.72b > Net Income 3.68b (YES >=105%, WARN >=100%) |
| Net Debt (-3.10b) to EBITDA (4.66b) ratio: -0.67 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (257.6m) change vs 12m ago -1.30% (target <= -2.0% for YES) |
| Gross Margin 86.28% (prev 86.11%; Δ 0.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 49.78% (prev 47.76%; Δ 2.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 348.4 (EBITDA TTM 4.66b / Interest Expense TTM 12.8m) >= 6 (WARN >= 3) |
Altman Z'' 6.22
| (A) 0.25 = (Total Current Assets 10.57b - Total Current Liabilities 4.48b) / Total Assets 24.86b |
| (B) 0.50 = Retained Earnings (Balance) 12.37b / Total Assets 24.86b |
| (C) 0.19 = EBIT TTM 4.46b / Avg Total Assets 23.55b |
| (D) 1.63 = Book Value of Equity 12.31b / Total Liabilities 7.54b |
| Total Rating: 6.22 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 86.34
| 1. Piotroski 7.0pt |
| 2. FCF Yield 2.92% |
| 3. FCF Margin 28.47% |
| 4. Debt/Equity 0.11 |
| 5. Debt/Ebitda -0.67 |
| 6. ROIC - WACC (= 14.60)% |
| 7. RoE 21.81% |
| 8. Rev. Trend 98.48% |
| 9. EPS Trend -18.70% |
What is the price of VRTX shares?
Over the past week, the price has changed by -2.06%, over one month by +6.52%, over three months by +12.16% and over the past year by +11.73%.
Is VRTX a buy, sell or hold?
- Strong Buy: 14
- Buy: 4
- Hold: 14
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the VRTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 491.9 | 8.5% |
| Analysts Target Price | 491.9 | 8.5% |
| ValueRay Target Price | 503.6 | 11.1% |
VRTX Fundamental Data Overview December 26, 2025
P/E Trailing = 32.3543
P/E Forward = 24.0385
P/S = 10.1257
P/B = 6.7274
P/EG = 0.5801
Beta = 0.321
Revenue TTM = 11.72b USD
EBIT TTM = 4.46b USD
EBITDA TTM = 4.66b USD
Long Term Debt = 1.83b USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 92.3m USD (from shortTermDebt, last fiscal year)
Debt = 1.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.10b USD (from netDebt column, last quarter)
Enterprise Value = 114.25b USD (118.71b + Debt 1.83b - CCE 6.29b)
Interest Coverage Ratio = 348.4 (Ebit TTM 4.46b / Interest Expense TTM 12.8m)
FCF Yield = 2.92% (FCF TTM 3.34b / Enterprise Value 114.25b)
FCF Margin = 28.47% (FCF TTM 3.34b / Revenue TTM 11.72b)
Net Margin = 31.35% (Net Income TTM 3.68b / Revenue TTM 11.72b)
Gross Margin = 86.28% ((Revenue TTM 11.72b - Cost of Revenue TTM 1.61b) / Revenue TTM)
Gross Margin QoQ = 86.52% (prev 86.25%)
Tobins Q-Ratio = 4.60 (Enterprise Value 114.25b / Total Assets 24.86b)
Interest Expense / Debt = 0.18% (Interest Expense 3.30m / Debt 1.83b)
Taxrate = 16.62% (215.9m / 1.30b)
NOPAT = 3.72b (EBIT 4.46b * (1 - 16.62%))
Current Ratio = 2.36 (Total Current Assets 10.57b / Total Current Liabilities 4.48b)
Debt / Equity = 0.11 (Debt 1.83b / totalStockholderEquity, last quarter 17.32b)
Debt / EBITDA = -0.67 (Net Debt -3.10b / EBITDA 4.66b)
Debt / FCF = -0.93 (Net Debt -3.10b / FCF TTM 3.34b)
Total Stockholder Equity = 16.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.78% (Net Income 3.68b / Total Assets 24.86b)
RoE = 21.81% (Net Income TTM 3.68b / Total Stockholder Equity 16.85b)
RoCE = 23.87% (EBIT 4.46b / Capital Employed (Equity 16.85b + L.T.Debt 1.83b))
RoIC = 22.07% (NOPAT 3.72b / Invested Capital 16.85b)
WACC = 7.47% (E(118.71b)/V(120.54b) * Re(7.58%) + D(1.83b)/V(120.54b) * Rd(0.18%) * (1-Tc(0.17)))
Discount Rate = 7.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.63%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈3.34b ; Y1≈2.19b ; Y5≈1.00b
Fair Price DCF = 77.62 (DCF Value 19.69b / Shares Outstanding 253.7m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -18.70 | EPS CAGR: -6.10% | SUE: -0.91 | # QB: 0
Revenue Correlation: 98.48 | Revenue CAGR: 11.11% | SUE: 0.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.84 | Chg30d=-0.053 | Revisions Net=+0 | Analysts=9
EPS next Year (2026-12-31): EPS=20.24 | Chg30d=+0.057 | Revisions Net=-4 | Growth EPS=+9.7% | Growth Revenue=+8.8%
Additional Sources for VRTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle